Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Other Non-Current Liabilities of $280000.0 for Q1 2026, up 33.97% on a QoQ basis from $209000.0 in Q4 2025, and up 8.11% year-over-year from $259000.0 in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $280000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 8.11% year-over-year to $280000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280000.0 (up 8.11% YoY) and the FY2025 annual result came in at $209000.0, down 33.65% from the prior year.
- Other Non-Current Liabilities was $280000.0 for Q1 2026 at Catalyst Pharmaceuticals, up from $209000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14.7 million in Q3 2022 and bottomed at $161000.0 in Q3 2025.
- A 5-year average of $4.7 million and a median of $2.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities tumbled 94.22% — and 2026, when it increased 8.11%.
- Catalyst Pharmaceuticals' Other Non-Current Liabilities stood at $14.1 million in 2022, then plunged by 78.8% to $3.0 million in 2023, then tumbled by 89.44% to $315000.0 in 2024, then plunged by 33.65% to $209000.0 in 2025, then soared by 33.97% to $280000.0 in 2026.
- Business Quant data shows CPRX's Other Non-Current Liabilities at $280000.0 in Q1 2026, $209000.0 in Q4 2025, and $161000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 309,000.00 |
| Mar 31, 2025 | 259,000.00 |
| Dec 31, 2024 | 315,000.00 |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | 12.72 Mn |
| Mar 31, 2023 | 13.39 Mn |
| Dec 31, 2022 | 14.06 Mn |
| Sep 30, 2022 | 14.75 Mn |
| Jun 30, 2019 | 801,264.00 |
| Dec 31, 2018 | 154,799.00 |
| Sep 30, 2018 | 164,781.00 |
| Jun 30, 2018 | 143,335.00 |
| Mar 31, 2018 | 150,395.00 |